News & insights
Check out our latest updates
Adding speech to a CANTAB battery in Alzheimer’s disease/MCI research
What can speech reveal about cognitive change in mild cognitive impairment and Alzheimer’s disease? We explore the evidence for combining Winterlight speech assessments with CANTAB, and what researchers should consider when adding speech measures to their studies.
Advancing Alzheimer’s prevention: Are clinical trials ready for earlier interventions?Â
Explore how the FDA’s Alzheimer’s Prevention Accelerator could advance earlier interventions, with digital cognitive assessments and biomarkers supporting more sensitive clinical trial endpoints.
Cambridge Cognition joins Imperial College-led NHS study bringing earlier Alzheimer’s diagnosis into primary care
Cambridge Cognition joins an Imperial College-led NHS study exploring how to bring earlier Alzheimer’s diagnosis into primary care.
Measuring speech in schizophrenia spectrum disorders
A practical guide to speech features, elicitation tasks and study design
First new CANTAB® product features developed & launched from the landmark INTUITION project
First new CANTAB® product features developed & launched from the landmark INTUITION project Cambridge Cognition (AIM: COG), the neuroscience technology company, announces two new product features for its CANTAB digital cognitive assessments derived from analysis of data from the INTUITION project. ​​​Application of Expanded Normative Dataset – Increased Sensitivity and...
